UPDATED: Sanofi’s and Regeneron’s Praluent wins top billing on UnitedHealth Group’s formulary

Eric Palmer

Sanofi and Regeneron's will be Group's "preferred" drug for treating superhigh LDL cholesterol. The partners said that Group will provide preferred access to both doses for the injected Praluent through OptumRx and UnitedHealthcare across a spectrum of commercial, Medicare, and Managed Medicaid patients.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS